
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
| signs and symptoms pathological conditions | D013568 |
Brand Name | Status | Last Update |
|---|---|---|
| dilantin | ANDA | 2025-10-02 |
| dilantin infatabs | ANDA | 2025-07-10 |
| dilantin kapseals | 2009-05-28 | |
| dilantin-125 | New Drug Application | 2023-02-02 |
| extended phenytoin sodium | ANDA | 2025-08-07 |
| phenytek | ANDA | 2025-01-29 |
| phenytoin | ANDA | 2025-09-17 |
| phenytoin infatabs | ANDA | 2025-06-27 |
| phenytoin sodium | ANDA | 2025-09-02 |

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Glioblastoma | D005909 | EFO_0000515 | — | 1 | — | — | — | — | 1 |
| Glioma | D005910 | EFO_0000520 | — | 1 | — | — | — | — | 1 |
| Gliosarcoma | D018316 | — | — | 1 | — | — | — | — | 1 |
| Drug common name | Phenytoin |
| INN | phenytoin |
| Description | Phenytoin is a imidazolidine-2,4-dione that consists of hydantoin bearing two phenyl substituents at position 5. It has a role as an anticonvulsant, a teratogenic agent, a drug allergen and a sodium channel blocker. It is functionally related to a hydantoin. |
| Classification | Small molecule |
| Drug class | antiepileptics (hydantoin derivatives) |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | O=C1NC(=O)C(c2ccccc2)(c2ccccc2)N1 |
| PDB | — |
| CAS-ID | 57-41-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL16 |
| ChEBI ID | 8107 |
| PubChem CID | 1775 |
| DrugBank | DB00252 |
| UNII ID | 6158TKW0C5 (ChemIDplus, GSRS) |






